Duvelisib
| Overview | |
| Catalog # | bs-83019c-5-mg |
| Product Name | Duvelisib |
| Specifications | |
| Storage Buffer | White solid |
| Storage Condition | -20°C |
| Target | |
| Product Information | Duvelisib (1201438-56-3) is a potent and selective (IC50’s: PI3Kα = 1602nM, PI3Kβ = 85nM, PI3Kδ= 2.5nM, PI3Kγ = 27nM) dual PI3Kδ/γ inhibitor.1 It inhibits B and T cell proliferation, blocks neutrophil migration, and inhibits basophil activation. Duvelisib antagonizes B-cell receptor crosslinking activated pro-survival signals in primary chronic lymphocytic leukemia cells.2 Duvelisib also shows preclinical/clinical activity against other hematologic malignancies such as Non-Hodgkins lymphoma, T-cell lymphoma, ande others.3,4 Useful clinical agent for the treatment of various blood cancers. Low-dose treatment of T-cell-inflamed tumor models of head and neck cancers with Duvelisib enhanced responses to PD-L1 blockade via suppression of myeloid-derived suppressor cells.5 Higher doses reversed the effect due to suppression of tumor-infiltrating T lymphocytes |
| Description | CAS Number: 1201438-56-3 Chemical Name: 8-Chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]isoquinolin-1-one Molecular weight: 416.87 Formula: C22H17ClN6O Solubility: DMSO (>25 mg/ml) Physical Properties: White solid Purity: 98% by HPLC NMR (Conforms) |
Powered by Bioz